Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion. News Sports Lifestyle Advertise Opinion Obituaries eNewspaper Legals.

Novo Nordisk, which is owned by Novo Holdings, will directly purchase the Bloomington location and two other fill-finish sites in Europe from its parent company. Catalent, a third-party manufacturer ...

The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know ...

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity ... Brussels in Belgium, and Bloomington, ...

Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.

Novo Nordisk is not the only company that has realized the potential of the GLP-1 market, ... Agnani (Italy), Brussels (Belgium) and Bloomington (United States). Through this acquisition, ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...